Critical appraisal of trastuzumab in treatment of advanced stomach cancer

Figures & data

Figure 1 Antitumor effects of trastuzumab.

Abbreviations: ECD, extracellular domain; VEGF, vascular endothelial growth factor; PI3K, phosphoinositide 3-kinase.

Table 1 Trastuzumab in gastric cancer: Preclinical and clinical trials

Authors	Type of study	n	Comments
Gong et al^Citation66	Preclinical	Cell lines	Antitumor activity
	T + D
Cortés-Funes et al^Citation67	Phase II	21	PR 35%
	T + C		SD 17%
Egamberdiev et al^Citation68	Phase II	16	OR 55%
	T + C		OS 8 months
Van Cutsem E et al^Citation69	Phase III T + Cap/5-FU CT alone	597	OS (P = 0.0048, death risk reduction by 26%)
			13.5 months
			11.1 months

Abbreviations: T, trastuzumab; C, cisplatin; D, doxorubicin; Cap, capecitabine; CT, chemotherapy; PR, partial response; SD, stable disease; OS, overall survival; OR, objective response; 5-FU, 5-fluorouracil.

GongSJJinCJRhaSYGrowth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell linesCancer Lett2004214221522415363548

 PubMed Web of Science ®Google Scholar

Cortés-FunesHRiveraFAlésIPhase II of trastuzumab and cisplatin in patients (pts) with advanced gastric cancer (AGC) with HER2/neu overexpression/amplificationJ Clin Oncol200725Suppl 18S4613

 Web of Science ®Google Scholar

EgamberdievDMDjuraevMDTuydjanovaKNematovONOur experience in the use of trastuzumab in patients with advanced stomach cancerAnn Oncol201021Suppl 8S839

 Google Scholar

Van CutsemEKangYChungHToGA Trial InvestigatorsTrastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomized controlled trialLancet2010376974268769720728210

 PubMed Web of Science ®Google Scholar